✦ LIBER ✦

18 NSCLC second line therapy with erlotinib: review of patients' outcomes

✍ Scribed by Urquhart, G.; Semple, E.; Steven, E.; Kerr, K.; Nicolson, M.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

24 Outcome in metastatic NSCLC without E

✍ Dua, D.; Montes, A.; Warner, M.; Spicer, J.; Lal, R. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 48 KB

414 Correlation of mutations in EGFR wit

✍ D. Eberhard; L. Amler; A. Goddard; W. Ince; T. Januario; K. Hillan; M. Ostland; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 143 KB

Clinical surrogate markers of survival i

✍ Cedrés, Susana; Prat, Aleix; Martínez, Pablo; Pallisa, Esther; Sala, Gemma; Andr 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 341 KB

29 The use of erlotinib as second line t

✍ Reeve, N.; Cook, M.; Keshri, A.; O'Sullivan, B.; Taniere, P.; Ghafoor, Q. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 149 KB

The association of clinical outcome to f

✍ Mhd Y. Al-Marrawi, Brian I. Rini, Lauren C. Harshman, Georg Bjarnason… 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 269 KB

Disease burden and treatment outcomes in

✍ Kimberly A. Boswell; Xufang Wang; Manasee V. Shah; Matti S. Aapro 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 143 KB